Journal of Clinical Oncology
Articles in this Issue
Biomarker-driven and evidence-based therapy for metastatic colorectal cancer (BEAT-CRC): A system-wide initiative to increase access to biomarker-driven therapy in a large practice network.
108 Background: Colorectal cancer (CRC) remains the second leading cause of cancer deaths worldwide, with ≥90% of these de...
Low-dose radiotherapy followed by chemoimmunotherapy in neoadjuvant treatment of locally advanced esophageal squamous cell carcinoma: A phase II STIMULATION-01 clinical trial.
348 Background: Neoadjuvant chemoimmunotherapy has shown promise in resectable esophageal squamous cell carcinoma (ESCC),...
Phase 2 trial of CBX-12 for metastatic chemotherapy-refractory microsatellite stable colorectal cancer (ETCTN 10707).
TPS259 Background: Despite currently approved therapies, most patients with metastatic colorectal cancer (mCRC) progress t...
Assessment of the prevalence of germline pathogenic variants (GPV) in neuroendocrine neoplasms (NENs): A systematic review and meta-analysis.
629 Background: NENs are a heterogeneous group of tumors with variable clinical behavior. While most NENs occur sporadical...
First-in-human study of an implantable microdevice for personalized drug testing in colorectal liver metastases.
TPS278 Background: Colorectal liver metastases (CRLM) are the leading cause of death in metastatic colorectal cancer. Stan...
Real world outcomes comparing the use of GLP-1 agonists in patients with hepatocellular cancer (HCC) and comorbid obesity: A propensity score matched analysis from Global Federated Health Research Network.
517 Background: Hepatocellular carcinoma (HCC) is a major cause of cancer related morbidity and mortality worldwide, with...
AI-assisted automated abstraction for enhanced patient insights in gastrointestinal cancers.
843 Background: Circulating tumor DNA (ctDNA) in patients diagnosed with cancer has emerged as a critical biomarker to det...
Colorectal cancer readmissions: Identifying high-risk patients and drivers of cost.
52 Background: Colorectal cancer was the second highest contributor to treatment costs in 2020, accounting for 11.6% of al...
Nivolumab plus chemotherapy in HER2-negative metastatic gastric, GEJ, and esophageal adenocarcinoma: A CheckMate 649 real-world validation study.
326 Background: CheckMate 649 established nivolumab plus chemotherapy as first-line standard of care for HER2-negative adv...
Comparative outcomes of apixaban and rivaroxaban in colon cancer patients with venous thromboembolism.
176 Background: Patients with colon cancer complicated by venous thromboembolism (VTE) frequently require anticoagulation....
Assessing barriers to cancer care in a war zone: A study of challenges facing patients with GI cancers in Syria.
809 Background: Barriers to necessary care can pose a significant burden on patients with cancer, even more so in places o...
The expanding utility of diagnostic laparoscopy in pancreatic ductal adenocarcinoma.
658 Background: Pancreatic ductal adenocarcinoma (PDAC) is often accompanied by radiographically occult metastatic disease...
Clinical outcomes in advanced gastric cancer among elderly patients (≥80 years old) treated with chemotherapy.
351 Background: In aging societies, the proportion of elderly patients with advanced gastric cancer (AGC) is increasing; h...
AMIGO: A phase 2 trial of amivantamab in <i>EGFR</i> or <i>MET-</i> amplified gastroesophageal adenocarcinoma (GEA).
394 Background: EGFR (~7%) and c-MET (~5%) amplifications are...
Pyroptosis and gasdermin expression in metastatic colorectal cancer.
211 Background: Pyroptosis is a lytic and inflammatory form of programmed cell death mediated by gasdermin proteins. It ma...
Legal Guidance and Advocacy for Caregivers (LEGACY CARE): A pilot clinical trial for patients with colorectal cancer and their caregivers.
TPS249 Background: Patients with colorectal cancer and their caregivers often face financial, legal, and administrative bu...
Prognostic indicators in Lynch syndrome–associated stage IV colorectal cancer treated with pembrolizumab: A multicenter TriNetX database study.
172 Background: Lynch syndrome is the most common hereditary syndrome associated with colorectal cancer (CRC). Lynch syndr...
Evaluating the prognostic impact of IDH mutations in intrahepatic cholangiocarcinoma.
598 Background: Mutations in isocitrate dehydrogenase 1 and 2 ( IDH1 ,...
WNT pathway alterations in bevacizumab-treated early-onset colorectal cancer: An artificial intelligence–driven and disparity-aware precision oncology analysis.
235 Background: The WNT signaling pathway, dominated by APC and related regulators, is central to colorectal cancer (CRC),...
A randomized, double-blinded, international phase III trial comparing HLX22 in combination with trastuzumab and chemotherapy versus trastuzumab and chemotherapy with or without pembrolizumab for first-line treatment for HER2-positive locally advanced or metastatic G/GEJ cancer.
TPS467 Background: Combination therapy with trastuzumab and chemotherapy is the first-line systemic treatment for human ep...
Molecular and immune landscape of early-onset versus average-onset well-differentiated enteropancreatic neuroendocrine tumors.
643 Background: The incidence of neuroendocrine tumors (NETs) has increased over the past few decades, especially among yo...
Impact of proton pump inhibitors and antibiotics on survival in immunotherapy treated gastrointestinal cancers.
836 Background: Despite significant progress in cancer immunotherapy, a substantial proportion of patients up to 70% exper...
ARTEMIDE-Gastric01: A phase 3 randomized study of rilvegostomig with fluoropyrimidine and trastuzumab deruxtecan (T-DXd) as first-line (1L) treatment for locally advanced or metastatic HER2-positive gastric or gastroesophageal junction cancer (GC/GEJC).
TPS460 Background: Patients with GC/GEJC often present with advanced disease, and prognosis for these patients is poor, wi...
Efficacy of regorafenib in patients with advanced biliary tract cancer: An updated systematic review and meta-analysis.
584 Background: Biliary tract cancer (BTC), or cholangiocarcinoma, is an aggressive and fatal malignancy that forms in the...
Evaluating the efficacy and safety of immunotherapy combinations as first-line treatment for hepatocellular carcinoma: A meta-analysis.
575 Background: Hepatocellular carcinoma (HCC) ranks among the leading causes of cancer-related deaths globally, with limi...